QNCX · As filed with the SEC
Quince Therapeutics income statement, by quarter
The statement as Quince Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating expenses: | ||||||||
| Research and development | 5,461,000 | 6,845,000 | — | 8,083,000 | 6,553,000 | 8,145,000 | — | 4,916,000 |
| Acquired in-process research and development | 59,000,000 | — | — | — | — | — | — | — |
| General and administrative | 16,626,000 | 4,267,000 | — | 3,281,000 | 3,342,000 | 4,789,000 | — | 3,630,000 |
| Goodwill impairment charge | — | — | — | 0 | 0 | — | — | 0 |
| Intangible asset impairment charge | — | — | — | — | — | — | 0† | 0 |
| Fair value adjustment for contingent consideration | — | — | — | — | — | — | 1,903† | (2,683) |
| Gain on Orphai Acquisition | (1,305,000) | — | — | — | — | — | — | — |
| Intangible asset impairment charge | 0 | 67,808,000 | — | — | — | — | — | — |
| Fair value adjustment for contingent consideration | 0 | (64,330,000) | — | 2,066,000 | 532,000 | 1,924,000 | — | — |
| Total operating expenses | 79,782,000 | 14,590,000 | — | 13,430,000 | 10,427,000 | 14,858,000 | — | 5,863,000 |
| Loss from operations | (79,782,000) | (14,590,000) | — | (13,430,000) | (10,427,000) | (14,858,000) | — | (5,863,000) |
| Fair value adjustment for long-term debt | — | — | — | — | (501,000) | (444,000) | — | (449,000) |
| Fair value adjustment for debt | 0 | 12,168,000 | — | (549,000) | — | — | — | — |
| Fair value adjustment for warrants | — | — | — | 291,000 | (4,464,000) | — | — | — |
| Fair value adjustment for warrants | 4,507,000 | 31,116,000 | — | — | — | — | — | — |
| Warrant issuance costs | (874,000) | — | — | (42,000) | (872,000) | — | — | — |
| Interest income | 584,000 | 160,000 | — | 300,000 | 311,000 | 406,000 | — | 683,000 |
| Other (expense) income, net | 152,000 | 1,719,000 | — | (58,000) | (29,000) | (87,000) | — | 150,000 |
| Net loss before provision for income taxes | — | — | — | — | — | (14,983) | — | — |
| Net loss before income tax expense | (75,413,000) | 30,573,000 | — | (13,488,000) | (15,982,000) | — | — | (5,479,000) |
| Income tax benefit (expense) | (75,000) | 5,339,000 | — | 46,000 | (67,000) | (47,000) | — | (13,000) |
| Net income (loss) | (75,488,000) | 35,912,000 | — | (13,442,000) | (16,049,000) | (15,030,000) | — | (5,492,000) |
| Other comprehensive loss: | ||||||||
| Foreign currency translation adjustments | — | — | — | — | — | — | (3,363)† | 2,158 |
| Foreign currency translation adjustments | (355,000) | (1,135,000) | — | 125,000 | 4,216,000 | 2,045,000 | — | — |
| Unrealized loss on available-for-sale securities | 0 | (5,000) | — | 12,000 | (17,000) | (53,000) | — | 174,000 |
| Total comprehensive loss | (75,843,000) | 34,772,000 | — | (13,305,000) | (11,850,000) | (13,038,000) | — | (3,160,000) |
| Net loss per share - basic (in USD per share) | (12.31) | 3.60 | — | (0.25) | (0.34) | (0.34) | — | (0.13) |
| Net loss per share - diluted( (in USD per share) | (12.31) | 2.88 | — | (0.25) | (0.34) | (0.34) | — | (0.13) |
| Weighted average shares of common stock and in-substance common stock outstanding - basic (in shares) | 6,132,845 | 9,120,267 | — | 53,951,371 | 46,686,239 | 43,941,185 | — | 43,164,136 |
| Weighted average shares of common stock and in-substance common stock outstanding - diluted (in shares) | 6,132,845 | 9,190,354 | — | 53,951,371 | 46,686,239 | 43,941,185 | — | 43,164,136 |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.